Leopold Shana R, Abdelraouf Kamilia, Nicolau David P, Agresta Hanako, Johnson Jethro, Teter Kathleen, Dunne Wm Michael, Broadwell David, van Belkum Alex, Schechter Lisa M, Sodergren Erica J, Weinstock George M
The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, United States.
Front Microbiol. 2022 Feb 17;13:813849. doi: 10.3389/fmicb.2022.813849. eCollection 2022.
There is a current need for enhancing our insight in the effects of antimicrobial treatment on the composition of human microbiota. Also, the spontaneous restoration of the microbiota after antimicrobial treatment requires better understanding. This is best addressed in well-defined animal models. We here present a model in which immune-competent or neutropenic mice were administered piperacillin-tazobactam (TZP) according to human treatment schedules. Before, during and after the TZP treatment, fecal specimens were longitudinally collected at established intervals over several weeks. Gut microbial taxonomic distribution and abundance were assessed through culture and molecular means during all periods. Non-targeted metabolomics analyses of stool samples using Quadrupole Time of Flight mass spectrometry (QTOF MS) were also applied to determine if a metabolic fingerprint correlated with antibiotic use, immune status, and microbial abundance. TZP treatment led to a 5-10-fold decrease in bacterial fecal viability counts which were not fully restored during post-antibiotic follow up. Two distinct, relatively uniform and reproducible restoration scenarios of microbiota changes were seen in post TZP-treatment mice. Post-antibiotic flora could consist of predominantly Firmicutes or, alternatively, a more diverse mix of taxa. In general, the pre-treatment microbial communities were not fully restored within the screening periods applied. A new species, closely related to , , and , became predominant post-treatment in a significant proportion of mice, identified by 16S rRNA gene sequencing. Principal component analysis of QTOF MS of mouse feces successfully distinguished treated from non-treated mice as well as immunocompetent from neutropenic mice. We observe dynamic but distinct and reproducible responses in the mouse gut microbiota during and after TZP treatment and propose the current murine model as a useful tool for defining the more general post-antibiotic effects in the gastro-intestinal ecosystem where humanized antibiotic dosing may ultimately facilitate extrapolation to humans.
当前需要增强我们对抗菌治疗对人类微生物群组成影响的认识。此外,抗菌治疗后微生物群的自发恢复也需要更好地理解。这在定义明确的动物模型中能得到最好的解决。我们在此展示一种模型,其中根据人类治疗方案给具有免疫能力或中性粒细胞减少的小鼠施用哌拉西林 - 他唑巴坦(TZP)。在TZP治疗前、治疗期间和治疗后,在数周内按既定间隔纵向收集粪便样本。在所有时间段通过培养和分子手段评估肠道微生物分类分布和丰度。还应用四极杆飞行时间质谱(QTOF MS)对粪便样本进行非靶向代谢组学分析,以确定代谢指纹是否与抗生素使用、免疫状态和微生物丰度相关。TZP治疗导致粪便细菌活力计数下降5 - 10倍,在抗生素治疗后的随访期间未完全恢复。在TZP治疗后的小鼠中观察到微生物群变化的两种不同、相对均匀且可重复的恢复情况。抗生素治疗后的菌群可能主要由厚壁菌门组成,或者是种类更多样的混合菌群。一般来说,在所应用的筛查期内,治疗前的微生物群落未完全恢复。通过16S rRNA基因测序鉴定,一种与[具体物种1]、[具体物种2]和[具体物种3]密切相关的新物种在相当比例的小鼠治疗后成为优势物种。对小鼠粪便的QTOF MS进行主成分分析成功区分了治疗组和未治疗组小鼠以及具有免疫能力和中性粒细胞减少的小鼠。我们观察到在TZP治疗期间和治疗后小鼠肠道微生物群有动态但不同且可重复的反应,并提出当前的小鼠模型作为一种有用工具,用于确定胃肠道生态系统中更普遍的抗生素后效应,其中人性化的抗生素给药最终可能有助于外推至人类。